Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia

Computational Biology and Chemistry

Volumn 34, Issue 3, 2010, Pages 184-192

  Burguillo, Francisco J ^a   Martin, Javier ^b   Barrera, Inmaculada ^b   Bardsley, William G ^c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CML; Gene expression; Imatinib resistance; Meta analysis; Microarrays

Indexed keywords

CHRONIC MYELOGENOUS LEUKEMIA; DATA SETS; DIFFERENTIALLY EXPRESSED GENE; GENE EXPRESSION DATA; IMATINIB; IMATINIB RESISTANCE; META-ANALYSIS; MICROARRAY DATA; POTENTIAL VALUES; QUANTITATIVE INFORMATION; REANALYSIS;

MICROARRAYS;

GENE EXPRESSION;

IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; DNA MICROARRAY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; META ANALYSIS; STATISTICS;

DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; PYRIMIDINES;

EID: 77955431417     PISSN: 14769271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compbiolchem.2010.06.003     Document Type: Article

References (48)

1. J.F. Apperley Part I. Mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol. 8 2007 1018 1029
2. W.G. Bardsley SIMFIT Statistical Package 2009 University of Manchester UK
3. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J. R. Stat. Soc. B 57 1995 289 300
4. P. Cahan, F. Rovegno, D. Mooney, J.C. Newman, G. St Laurent 3rd, and T.A. McCaffrey Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization Gene 401 2007 12 18
5. W.G. Cochran The combination of stimates from different experiments Biometrics 10 1954 101 129
6. L.C. Crossman, M. Mori, Y.C. Hsieh, T. Lange, P. Paschka, C.A. Harrington, K. Krohn, D.W. Niederwieser, R. Hehlmann, A. Hochhaus, B.J. Druker, and M.W. Deininger In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures Haematologica 90 2005 459 464
7. J.K. Choi, U. Yu, S. Kim, and O.J. Yoo Combining multiple microarray studies and modeling interstudy variation Bioinformatics 19 Suppl. 1 2003 i84 i90
8. Y. Dai, M. Rahmani, S.J. Corey, P. Dent, and S. Grant A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 J. Biol. Chem. 279 2004 34227 34239
9. H. de Lavallade, P. Finetti, N. Carbuccia, J.S. Khorashad, A. Charbonnier, L. Foroni, J.F. Apperley, N. Vey, F. Bertucci, D. Birnbaum, and M.J. Mozziconacci A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia Leuk. Res. 2009 doi:10.1016/j.leukres.2009.09.026
10. M. Deininger, E. Buchdunger, and B.J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2005 2640 2653
11. G. Dennis Jr., B.T. Sherman, D.A. Hosack, J. Yang, W. Gao, H.C. Lane, and R.A. Lempicki DAVID: database for annotation, visualization, and integrated discovery Genome Biol. 4 2003 3
12. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
13. N.J. Donato, J.Y. Wu, J. Stapley, H. Lin, R. Arlinghaus, B.B. Aggarwal, S. Shishodia, M. Albitar, K. Hayes, H. Kantarjian, and M. Talpaz Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia Cancer Res. 64 2004 672 677 (Pubitemid 38120909)
14. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, R.A. Larson, and I.R.I.S. Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N. Engl. J. Med. 355 2006 2408 2417 (Pubitemid 44903745)
15. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
16. S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H.M. Kantarjian The biology of chronic myeloid leukemia N. Engl. J. Med. 341 1999 164 172
17. R.A. Fisher Statistical Methods for Research Work 1931 Oliver and Boyd Edinburg and London
18. O. Frank, B. Brors, A. Fabarius, L. Li, M. Haak, S. Merk, U. Schwindel, C. Zheng, M.C. Muller, N. Gretz, R. Hehlmann, A. Hochhaus, and W. Seifarth Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients Leukemia 20 2006 1400 1407
19. A. Hochhaus, and T. Hughes Clinical resistance to imatinib: mechanisms and implications Hematol. Oncol. Clin. North Am. 18 2004 641-656, ix
20. F. Hong, and R. Breitling A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments Bioinformatics 24 2008 374 382
21. W. Huang da, B.T. Sherman, and R.A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat. Protoc. 4 2009 44 57
22. J.E. Hunter, F.L. Schmidt, and J.B. Jackson Meta-analysis: Cumulating Research Findings Across Studies 1982 Sage Publications Beverly-Hills
23. E. Jabbour, J.E. Cortes, and H.M. Kantarjian Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin. Proc. 84 2009 161 169
24. M.P. Jones, T.W. O'Gorman, J.H. Lemke, and R.F. Woolson A Monte Carlo investigation of homogeneity tests of the odds ratio under various sample size configurations Biometrics 45 1989 171 181
25. D.J. Joske Chronic myeloid leukaemia: the evolution of gene-targeted therapy Med. J. Aust. 189 2008 277 282
26. Y. Kaneta, Y. Kagami, T. Katagiri, T. Tsunoda, I. Jin-nai, H. Taguchi, H. Hirai, K. Ohnishi, T. Ueda, N. Emi, A. Tomida, T. Tsuruo, Y. Nakamura, and R. Ohno Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis Jpn. J. Cancer Res. 93 2002 849 856
27. O. Larsson, K. Wennmalm, and R. Sandberg Comparative microarray analysis OMICS 10 2006 381 397
28. L.A. McLean, I. Gathmann, R. Capdeville, M.H. Polymeropoulos, and M. Dressman Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib Clin. Cancer Res. 10 2004 155 165
29. E.R. Morrissey, and R. Diaz-Uriarte Pomelo II: finding differentially expressed genes Nucleic Acids Res. 37 2009 W581 W586
30. P.C. Nowell, and D.A. Hungerford A minute chromosome in human granulocytic leukemia Science 132 1960 1497
31. R. Ohno Treatment of chronic myeloid leukemia with imatinib mesylate Int. J. Clin. Oncol. 11 2006 176 183
32. R. Ohno, and Y. Nakamura Prediction of response to imatinib by cDNA microarray analysis Semin. Hematol. 40 2003 42 49
33. A. Quintas-Cardama, and J. Cortes Molecular biology of bcr-abl1-positive chronic myeloid leukemia Blood 113 2009 1619 1630
34. P. Ramirez, and J.F. DiPersio Therapy options in imatinib failures Oncologist 13 2008 424 434
35. D.R. Rhodes, T.R. Barrette, M.A. Rubin, D. Ghosh, and A.M. Chinnaiyan Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer Cancer Res. 62 2002 4427 4433
36. R. Rosenthal Meta-analytic Procedures for Social Research 1984 Sage Beverly-Hills
37. J.D. Rowley Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293
38. S. Schmidt, G. Gastl, and D. Wolf Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia Leuk. Lymphoma 49 2008 643 647
39. D.W. Sherbenou, and B.J. Druker Applying the discovery of the Philadelphia chromosome J. Clin. Invest. 117 2007 2067 2074
40. J.R. Stevens, and R.W. Doerge Combining Affymetrix microarray results BMC Bioinform. 6 2005 57
41. S.A. Stouffer, E.A. Suchman, L.C. DeVinney, S.A. Star, and R.M.J. Williams The American Soldier: Adjustment during Army Life Vol. 1 1949 Princeton University Press Princeton
42. M. Suarez-Farinas, and M.O. Magnasco Comparing microarray studies Methods Mol. Biol. 377 2007 139 152
43. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc. Natl. Acad. Sci. U.S.A. 98 2001 5116 5121
44. R. Villuendas, J.L. Steegmann, M. Pollan, L. Tracey, A. Granda, E. Fernandez-Ruiz, L.F. Casado, J. Martinez, P. Martinez, L. Lombardia, L. Villalon, J. Odriozola, and M.A. Piris Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach Leukemia 20 2006 1047 1054
45. C. Walz, and M. Sattler Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML) Crit. Rev. Oncol. Hematol. 57 2006 145 164
46. A. Whitehead, and J. Whitehead A general parametric approach to the meta-analysis of randomized clinical trials Stat. Med. 10 1991 1665 1677
47. F.M. Wolf Meta-analysis: Quantitative Methods for Research Synthesis. Quantitative Applications in Social Sciences 1986 Sage Publications Beverly-Hills
48. A.S. Yong, and J.V. Melo The impact of gene profiling in chronic myeloid leukaemia Best Pract. Res. Clin. Haematol. 22 2009 181 190